Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Johnson and Johnson
Merck
AstraZeneca
McKinsey

Last Updated: August 10, 2022

CLINICAL TRIALS PROFILE FOR SELUMETINIB SULFATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Selumetinib Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00551070 ↗ Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Completed NRG Oncology Phase 2 2007-12-17 This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00551070 ↗ Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Completed National Cancer Institute (NCI) Phase 2 2007-12-17 This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00559949 ↗ Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed National Cancer Institute (NCI) Phase 2 2007-12-01 This phase II trial is studying how well selumetinib works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01085214 ↗ AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma Completed National Cancer Institute (NCI) Phase 2 2010-03-01 This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.
NCT01116271 ↗ Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec Completed AstraZeneca Phase 2 2010-04-01 The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.
NCT01166126 ↗ Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Terminated National Cancer Institute (NCI) Phase 2 2010-10-01 The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma
NCT01278615 ↗ Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2010-12-01 This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selumetinib Sulfate

Condition Name

Condition Name for Selumetinib Sulfate
Intervention Trials
Solid Tumours 5
Neurofibromatosis Type 1 4
Neurofibromatosis 1 3
Refractory Malignant Solid Neoplasm 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Selumetinib Sulfate
Intervention Trials
Neurofibromatosis 1 6
Neurofibromatoses 6
Neurofibroma 6
Melanoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Selumetinib Sulfate

Trials by Country

Trials by Country for Selumetinib Sulfate
Location Trials
United States 370
Canada 13
United Kingdom 4
Puerto Rico 4
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Selumetinib Sulfate
Location Trials
Maryland 16
Pennsylvania 16
Florida 15
North Carolina 14
California 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Selumetinib Sulfate

Clinical Trial Phase

Clinical Trial Phase for Selumetinib Sulfate
Clinical Trial Phase Trials
Phase 3 5
Phase 2 17
Phase 1/Phase 2 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Selumetinib Sulfate
Clinical Trial Phase Trials
Completed 16
Recruiting 8
Active, not recruiting 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Selumetinib Sulfate

Sponsor Name

Sponsor Name for Selumetinib Sulfate
Sponsor Trials
National Cancer Institute (NCI) 20
AstraZeneca 15
NRG Oncology 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Selumetinib Sulfate
Sponsor Trials
NIH 20
Industry 15
Other 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Johnson and Johnson
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.